Diabetes Care, Vol 22, Issue 6 925-927, Copyright © 1999 by American Diabetes Association

ARTICLES

Incidence of lactic acidosis in metformin users

M Stang, DK Wysowski and D Butler-Jones
Saskatchewan Health, Regina, Canada. mstang@health.gov.sk.ca

OBJECTIVE: The purpose of this study was to determine the incidence of lactic acidosis in a geographically defined population of metformin users. RESEARCH DESIGN AND METHODS: The study was based on a historical cohort from the Saskatchewan Health administrative databases. Individuals with a metformin prescription dispensed between 1980 and 1995 inclusive were eligible for the cohort. Person-years of exposure were calculated. Cases were defined by hospital discharge with a diagnosis of acidosis (International Classification of Diseases, Ninth Revision code: 276.2) and confirmation by chart review of a blood lactate level > or = 5 mmol/l. Death registrations of individuals dying within 120 days of a metformin prescription were also reviewed. RESULTS: During the study period, 11,797 residents received one or more metformin prescriptions, resulting in 22,296 person-years of exposure. There were 10 subjects who had hospital discharges with a diagnosis of acidosis. However, primary record review revealed only two cases with laboratory findings of elevated blood lactate levels, for an incidence rate of 9 cases per 100,000 person-years of metformin exposure. In both cases, other factors besides metformin could have contributed to the lactic acidosis. No additional cases were found on review of death registrations. CONCLUSIONS: From 1980 through 1995, the incidence rate of lactic acidosis was 9 per 100,000 person-years (95% CI 0-21) in patients dispensed metformin in Saskatchewan, Canada. This incidence rate was derived from a population with complete ascertainment of hospitalizations and deaths associated with lactic acidosis in metformin users. It is similar to previously published rates based on passive reporting of cases, and it is well below the lactic acidosis rate of 40-64 per 100,000 patient-years in patients prescribed phenformin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Balik, P. Waldauf, K. Glocknerova, and D. Kusova Lactate-buffered dialysis in cardiogenic shock associated with severe combined lactic acidosis NDT Plus, April 1, 2008; 1(2): 103 - 105. [Abstract] [Full Text] [PDF]

				R. D. Bloom and M. F. Crutchlow New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S38 - S48. [Abstract] [Full Text] [PDF]

				H. A. Spiller and T. S. Sawyer Toxicology of oral antidiabetic medications Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 929 - 938. [Abstract] [Full Text] [PDF]

				J. McCormack, K. Johns, and H. Tildesley Metformin's contraindications should be contraindicated Can. Med. Assoc. J., August 30, 2005; 173(5): 502 - 504. [Full Text] [PDF]

				D. K. Wysowski and L. Swartz Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions Arch Intern Med, June 27, 2005; 165(12): 1363 - 1369. [Abstract] [Full Text] [PDF]

				F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study Circulation, February 8, 2005; 111(5): 583 - 590. [Abstract] [Full Text] [PDF]

				U. Panzer, S. Kluge, G. Kreymann, and G. Wolf Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2157 - 2158. [Full Text] [PDF]

				H. A Spiller and D. A Quadrani Toxic Effects from Metformin Exposure Ann. Pharmacother., May 1, 2004; 38(5): 776 - 780. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				F. A. Masoudi, Y. Wang, S. E. Inzucchi, J. F. Setaro, E. P. Havranek, J. M. Foody, and H. M. Krumholz Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure JAMA, July 2, 2003; 290(1): 81 - 85. [Abstract] [Full Text] [PDF]

				J. K Khan, M. Pallaki, S. R Tolbert, and T. R Hornick Lactic Acidemia Associated with Metformin Ann. Pharmacother., January 1, 2003; 37(1): 66 - 69. [Abstract] [Full Text] [PDF]

				R. J Sigal Review: metformin does not increase fatal or non-fatal lactic acidosis or blood lactate concentrations in type 2 diabetes mellitus Evid. Based Med., November 1, 2002; 7(6): 176 - 176. [Full Text] [PDF]

				F. C. LUFT Lactic Acidosis Update for Critical Care Clinicians J. Am. Soc. Nephrol., February 1, 2001; 12(90001): 15S - 19. [Abstract] [Full Text]